VAXX (Vaxxinity, NASDAQ) at $0.0075 on 19 Mar 2026: Earnings could change momentum

Today intraday VAXX stock is trading at $0.0075, up from a previous close of $0.0001, making it one of the top gainers on NASDAQ in the United States on 19 Mar 2026. The move reflects a thin-volume rally with volume 106 versus a 50-day average of 7,708 shares. Investors should note Vaxxinity, Inc. (VAXX) has an upcoming earnings announcement on 26 Mar 2026, which could rapidly change sentiment.

Intraday surge in VAXX stock and what the tape shows

VAXX stock jumped to $0.0075 intraday on NASDAQ on 19 Mar 2026, a move driven by a low prior close of $0.0001. The change registers as a very large percentage swing but occurred on thin volume (106), giving the gain limited liquidity confirmation.

The relative volume is 0.03, and the 50-day average price is $0.00319 versus a 200-day average of $0.00783, indicating recent volatility and sparse trading participation.

Drivers and news flow for VAXX stock

There was no company press release tied to the intraday spike, and market commentary referenced sector peer activity rather than company-specific catalysts. The most relevant calendar event is Vaxxinity’s earnings announcement set for 26 Mar 2026, which is likely to drive short-term volatility.

Vaxxinity’s pipeline includes UB-311 (Alzheimer’s), UB-312 (Parkinson’s), and UB-612 (COVID vaccine program), and trial updates or regulatory news could produce larger, sustained moves in VAXX stock.

VAXX stock fundamentals and valuation metrics

Vaxxinity, Inc. operates in the Healthcare / Biotechnology sector and shows an EPS of -0.45 and a current PE of -0.02, reflecting negative earnings. Market cap stands at $1,267,847.00, with shares outstanding 126,784,680.

Key ratios: price-to-book is 0.09, current ratio 1.89, and debt-to-equity 1.13. These figures signal a capital-light biotech with losses and modest cash per share $0.24, and typical risk for small-cap clinical-stage companies.

Technicals, volatility and short-term trading signals for VAXX stock

Momentum indicators are mixed: RSI 55.95 and ADX 65.65 point to a strong underlying trend but noisy price action. MFI sits at 98.58, indicating overbought conditions on the intraday move.

Price averages show a 50-day mean $0.00319 and 200-day mean $0.00783, so traders should expect wide intraday swings and low liquidity risk in VAXX stock.

Meyka AI rates VAXX stock and model forecast

Meyka AI rates VAXX with a score out of 100: 61.48 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 comparison, sector and industry performance, financial growth, key metrics, forecasts, analyst sentiment, and fundamental growth.

Meyka AI’s forecast model projects a monthly price of $0.01, implying an upside of 33.33% from the current price $0.0075. Forecasts are model-based projections and not guarantees. Analysts have not posted a consensus price target, so our model offers a data-driven reference point.

Risk, sector context and strategy for VAXX stock

VAXX stock carries typical biotech risks: trial failures, cash burn, and regulatory timing. Enterprise value is $11,504,847.00, highlighting leverage relative to market cap and the need for fundraising or partnership deals.

From a strategy view, short-term traders should manage position size due to low liquidity. Long-term investors should monitor clinical readouts and the 26 Mar 2026 earnings report. For coverage and peer context see MarketBeat analysis of peers.

Final Thoughts

VAXX stock is an intraday top gainer on 19 Mar 2026 but the jump occurs on thin volume (106), which raises caution about sustainability. Fundamentals show negative earnings per share -0.45 and modest cash per share $0.24, while technicals signal an overbought short-term move. Meyka AI’s forecast model projects $0.01 monthly for VAXX stock, a 33.33% implied upside from $0.0075, and our scenario price target range is $0.01 to $0.02 over the next 12 months depending on trial updates and earnings. These price targets are model-based and not guarantees. Use tight risk controls ahead of the 26 Mar 2026 earnings announcement, and consider the stock only as a speculative position given liquidity and pipeline risk. Meyka AI, an AI-powered market analysis platform, provides the grade and model forecast above to help frame risk and opportunity.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.